What is Omnicell's latest dividend and current dividend yield?

What guidance did Omnicell's management provide for the next earnings period?

What factors drove the changes in Omnicell's revenue and profit?

What were the key takeaways from Omnicell’s earnings call?

Did Omnicell beat or miss consensus estimates last quarter?

What were the key takeaways from Omnicell's earnings call?

What is the revenue and EPS growth rate for Omnicell year over year?

What is the market's earnings forecast for Omnicell next quarter?

- **Q2 Financial Outperformance**: Revenue $312M, EBITDA $67M, EPS $0.94 (all above guidance), driven by tariff refund and operational efficiency.
- **Strategic Moves**: Nnamdi Njoku appointed COO, Titan XT shipments begin Q3, OmniSphere ADS launches Q1 2027.
- **Competitive Wins**: First Titan XT conversion win, specialty pharmacy expansion, and multi-stakeholder pipeline growth.
- **Guidance Update**: 2026 product bookings $425M-$560M (wide range due to timing), EBITDA $175M-$185M, EPS $2.15-$2.30.
- **Risks**: Memory chip supply costs adding $6M, 50bps margin impact; competitive conversion cycles 6-18 months.

**【Management Opening Remarks】**
- David Unger outlined the call agenda, emphasizing Omnicell’s Q2 financial results, strategic priorities, and updated guidance. He highlighted the appointment of Nnamdi Njoku as COO and the company’s focus on innovation and operational efficiency.

**【CEO Summary Section】**
- **Q2 Financial Highlights**: Total revenue of $312M (high end of guidance), non-GAAP EBITDA of $67M, and EPS of $0.94. A one-time $15M tariff refund boosted results.
- **Strategic Appointments**: Nnamdi Njoku’s promotion to COO to accelerate execution and operational focus.
- **Market Trends**: Health systems prioritizing efficiency, automation, and enterprise-wide solutions. Increased pipeline activity for Titan XT and OmniSphere.
- **Competitive Positioning**: Omnicell solutions viewed as strategic, enterprise-wide platforms, driving multi-stakeholder evaluations.

**【COO Operational Update】**
- **Product Launches**: Titan XT shipments expected in Q3 2026, OmniSphere ADS general availability in Q1 2027.
- **Customer Wins**: First competitive Titan XT conversion win in Q2, with customers selecting Omnicell for cloud connectivity, AI-driven workflows, and flexible financing.
- **Specialty Pharmacy Growth**: New wins in Oregon, Arizona, and northwest Arizona, expanding clinical outcomes and patient experience.
- **Leasing Program**: Used to secure competitive wins, offering predictable spend and lifetime value economics.

**【CFO Financial Commentary】**
- **Q2 Financials**: Product revenue $175M, service revenue $137M. Non-GAAP gross margin 50% (boosted by $15M tariff refund). Free cash flow $56M.
- **Updated Guidance**: Full-year 2026 product bookings $425M-$560M (wide range due to pipeline timing uncertainty). Non-GAAP EBITDA $175M-$185M, EPS $2.15-$2.30.
- **Risk Factors**: Memory chip supply imbalance adding $6M in incremental costs, 50bps impact on gross margin.
- **Long-Term Outlook**: Strong pipeline, customer engagement, and innovation driving confidence in long-term growth.

**【Q&A Highlights】**
- **Booking Guidance Range**: Lower end reflects timing uncertainty, upper end maintained due to line-of-sight on large deals. Pipeline larger than recent years, but decisions take 6-18 months.
- **Competitive Conversions**: Customers evaluate Omnicell for reliability, service, and innovation. First competitive win in Q2, with multi-stakeholder evaluations slowing decision-making.
- **Leasing Strategy**: Used to extend sales cycles and showcase innovation. Leasing volume remains small but strategically impactful.
- **IV Product Line**: IVX workflow solution in development, with focus on semi-automated solutions for near-term demand. Central pharmacy and analytics integration planned for OmniSphere.


Omnicell Inc (OMCL) Q2 2026 Earnings Call Transcript

- **Q1 2026 Strong Execution:** $310M revenue (+15% YoY), Non-GAAP EBITDA $45M, EPS $0.55.
- **Gross Margin Expansion:** 46% (vs. 42% Q1 2025), driven by Connected Devices growth.
- **Titan XT Momentum:** Initial orders booked, hardware shipments Q2 2026, software Q1 2027.
- **Updated Guidance:** 2026 EBITDA $153-168M, EPS $1.80-2.00, ARR $680-700M.
- **Competitive Edge:** Positive customer response to OmniSphere workflows, $2.5B replacement opportunity.

**【CEO Summary Section】**
- Q1 2026 total revenue: $310 million (15% YoY growth), Non-GAAP EBITDA: $45 million, Non-GAAP EPS: $0.55.
- Core growth drivers: Connected Devices (20% YoY), Specialty Pharmacy Services (8% YoY), and recurring revenue streams.
- Strategic focus: Autonomous medication management via OmniSphere platform and Titan XT deployment.
- Competitive momentum: Positive customer feedback on Titan XT's guided workflows, DynamicRestock, and migration flexibility.
- Long-term opportunity: $2.5+ billion replacement cycle for XT installed base, with initial 2026 bookings weighted to H2.

**【CFO Financial Commentary】**
- Q1 2026 financial highlights:
  - Total revenue: $310 million (15% YoY), Product: $175 million (20% YoY), Service: $135 million (8% YoY).
  - Non-GAAP gross margin: 46% (vs. 42% Q1 2025), driven by product mix and cost management.
  - Free cash flow: $39 million (vs. $10 million Q1 2025).
- Updated 2026 guidance:
  - Total revenue: $1.215-1.255 billion.
  - Non-GAAP EBITDA: $153-168 million (up from $145-160 million).
  - Non-GAAP EPS: $1.80-2.00 (up from $1.65-1.85).
  - ARR: $680-700 million.
- Key assumptions: Linear revenue growth, $12 million tariff impact, 15% tax rate.

**【Q&A Key Highlights】**
- **Retail segment (EnlivenHealth):** Volumes increasing, focus on cost efficiency and omnichannel solutions.
- **Gross margin sustainability:** 46% Q1 reflects favorable mix and lapped investments; expect periodic fluctuations.
- **Titan XT adoption:** Initial orders booked, hardware shipments Q2 2026, software rollout Q1 2027.
- **Competitive conversions:** Pipeline strength driven by incumbent challenges; 2026 bookings include modest competitive wins.
- **EBITDA guidance:** Expansion rate >2x revenue growth, balanced with innovation investment.


Omnicell, Inc. (OMCL) Q1 2026 Earnings Call Transcript

- **ARR Growth**: 2025 exit ARR of $636 million (+10% YoY), guided to $680-700 million in 2026.
- **Titan XT Opportunity**: $2.5 billion replacement cycle over 8+ years, with H2 2026 shipments.
- **Financial Resilience**: Q4 2025 total revenue above guidance, despite 4% YoY gross margin decline.
- **Tariff Mitigation**: $15 million 2026 impact, offset by supply chain optimization.
- **Recurring Revenue Focus**: 2026 service revenue growth expected to outpace product revenue.

**【CEO Summary Section】**
- **Q4 2025 Performance**: Total revenue of $314 million, above midpoint of guidance, driven by strong product and service revenue growth. ARR exited Q4 at $636 million, up 10% YoY.
- **Titan XT Launch**: Introduced at ASHP Annual Meeting, with early positive feedback from customers. Expected to be available for shipment in H2 2026.
- **Three Growth Pillars**: 
  1. **Market Expansion**: Penetrating inpatient and outpatient care settings with solutions like XTExtend and Titan XT.
  2. **Recurring Revenue**: SaaS and service contracts (e.g., OmniSphere) now at $636 million ARR.
  3. **Technology Platform**: OmniSphere, a cloud-based platform, achieved HITRUST certification and is being adopted across health systems.
- **Competitive Wins**: Secured deals with major health systems in Louisiana, Texas, and New England, driving patient safety and efficiency.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: 
  - Total revenue: $314 million (+2% YoY)
  - Non-GAAP EPS: $0.40 (down 33% YoY due to reduced interest income)
  - Non-GAAP EBITDA: $37 million (down 19% YoY)
  - Free cash flow: $18 million
- **2026 Guidance**: 
  - Product bookings: $510-560 million
  - Total revenue: $1.215-1.255 billion
  - ARR: $680-700 million
  - Non-GAAP EBITDA: $145-160 million
- **Tariff Impact**: Anticipated $15 million hit in 2026, partially offset by cost control.
- **Cash Position**: $197 million as of Q4 2025, after debt repayment and share buybacks.

**【Q&A Highlights】**
- **Titan XT Adoption**: Expected $2.5 billion replacement cycle over 8+ years, with early pipeline activity post-ASHP launch.
- **Gross Margin Challenges**: Q4 product margin decline due to mix shift and tariffs; service margins improved 1% QoQ.
- **Investments**: $10 million in ERP upgrades for 2026, supporting long-term efficiency.
- **Competitive Wins**: 40% of Q4 bookings from competitive upgrades, driven by OmniSphere's platform value.
- **Cloud Strategy**: XTExtend consoles enable cloud access, positioning for future OmniSphere adoption.


Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript

- **Revenue Beat**: Q3 revenue $311M (+10% YoY), Non-GAAP EPS $0.51 vs. $0.56 prior year. Full-year guidance raised to $1.177B-$1.187B.
- **OmniSphere Expansion**: 60+ customers migrating to cloud platform; early adopters report efficiency gains. HITRUST-certified security.
- **Tariff Mitigation**: $6M Q3 impact, 2025 total $15M. 2026 actions to reduce impact below Q4 2025 run rate.
- **Innovation Push**: Modular robots, AI-driven pharmacy solutions, and ASHP 2025 product showcase.
- **340B Growth**: Over 50% new contracts from existing customers, ARR $610M-$630M.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $311 million, up 10% YoY, driven by point-of-care solutions like XTExtend. Non-GAAP EPS was $0.51, exceeding expectations.
- **OmniSphere Momentum**: Cloud-based platform achieved HITRUST certification, with early adopters and plans for full customer migration. Expansion into outpatient settings and government facilities.
- **Strategic Pillars**: Market expansion (nursing units, ORs), service contracts (subscriptions, software), and technology acceleration (AI, robotics). Completed $75M stock buyback, reducing shares by 5%.
- **Innovation Focus**: Autonomous pharmacy vision with AI and robotics; new compounding robot in limited release. ASHP 2025 showcase for new innovations.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 GAAP EPS $0.12, Non-GAAP EPS $0.51. Gross margin 44.2%. Free cash flow $14M, down from $27M prior quarter. Tariffs impacted Q3 profitability by $6M, expected to continue in Q4.
- **Guidance Update**: Full-year revenue raised to $1.177B-$1.187B, up from $1.13B-$1.16B. Non-GAAP EBITDA $140M-$146M, up from $130M-$145M. ARR $610M-$630M.
- **Tariff Mitigation**: Supply chain diversification to reduce 2026 impact. Q4 revenue $306M-$316M, EBITDA $37M-$43M.

**【Q&A Highlights】**
- **Robotics & Hardware**: Exploring humanoid robots for pharmacy; smaller, modular dispensing robots in development. Robotics integration into current products for efficiency.
- **OmniSphere Adoption**: 60+ customers on OmniCenter migrating to OmniSphere. Early adopters report improved visibility and efficiency.
- **IV Opportunity**: Ballad Health win for IV workflow solutions. Hub-and-spoke model based on health system size and throughput needs.
- **340B Growth**: Over half of new 340B contracts from existing customers. Regulatory headwinds offset by hospital focus on ROI, ARR growth expected.
- **Sales Cycle**: Consistent pipeline momentum, no significant cycle changes. Focus on point-of-care products with limited release compounding robot.
- **Tariff Impact**: Q3/Q4 $6M net impact, 2025 total $15M. 2026 mitigation efforts to reduce impact below Q4 2025 run rate.

Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue $291M (+5% YoY, +8% QoQ), driven by XTExtend wins and MedVision/MedTrack launches.
- **Margin Expansion**: Non-GAAP gross margin 44.7% (up 260bps QoQ), EPS $0.45 (vs. $0.26 QoQ).
- **Tariff Mitigation**: $15M 2025 net impact; price increases gaining traction, 2026 impact expected to decline.
- **Innovation Momentum**: HITRUST-certified Omnisphere platform, MedVision for outpatient clinics, MedTrackOR RFID solution.
- **Guidance Update**: 2025 revenue raised to $1.13B-$1.16B, EBITDA to $130M-$145M.

**【CEO Summary Section】**
- Reaffirmed full-year 2025 guidance for product bookings and ARR, modestly raised revenue, EBITDA, and EPS targets.
- Q2 revenue of $291M (+5% YoY, +8% QoQ) driven by XTExtend wins in Northeast, Nebraska, and Southern New York.
- Introduced MedVision for outpatient clinics and MedTrackOR RFID solution for operating rooms.
- Omnisphere platform achieved HITRUST certification, positioning as the industry's only med management company with this standard.
- Emphasized long-term strategy to evolve from device-centric to end-to-end medication management platform.

**【CFO Financial Commentary】**
- Q2 non-GAAP EPS: $0.45 (vs. $0.51 YoY, $0.26 QoQ), GAAP EPS: $0.12 (vs. $0.08 YoY, -$0.15 QoQ).
- Gross margin: 44.7% (up 50bps YoY, 260bps QoQ) due to higher volumes, pricing, and mix.
- Tariff impact: $2M net in Q2, expected $6M/Q in H2, with 2025 total net impact of $15M.
- Free cash flow: $27M (vs. $10M QoQ), cash: $399M.
- Raised 2025 revenue guidance to $1.13B-$1.16B (prev: $1.105B-$1.155B), EBITDA to $130M-$145M (prev: $120M-$145M).

**【Q&A Highlights】**
- **Competitive Landscape**: CEO notes hospitals remain active buyers despite macro uncertainty; Omnicell's tech platform and enterprise solutions differentiate from competitors.
- **Medicaid Cuts**: No pipeline delays observed; customers view automation as cost-saving solution.
- **IV Automation**: Q2 win with leading Southern California health system; product backlog growing.
- **Tariff Mitigation**: Price increases gaining market acceptance; 2026 tariff impact expected to decline.
- **Omnisphere Adoption**: All customers will migrate to platform over several years; recurring revenue opportunities from SaaS, subscriptions.
- **Recurring Revenue**: 50-50 split between product and services; XT Amplify driving product growth, consumables up 8% QoQ.


Omnicell (OMCL)-31 Jul 25-2025 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2025 revenue up 9% YoY to $270M, driven by XT Amplify (product +8%, services +10%).
- **Margin Pressure**: Gross margin 42.1% vs. 47.4% prior quarter due to lower volumes and tariffs.
- **Tariff Risk**: $40M EBITDA impact in 2025, with $35M in H2. 3-year nearshore plan 1/3 complete.
- **Customer Momentum**: Secured multi-site contracts with top 10 health systems for point-of-care automation.
- **Financial Resilience**: $387M cash reserves, generating $10M free cash flow despite headwinds.


**【CEO Summary Section】**
- Total revenue for Q1 2025 was $270 million, up 9% YoY, driven by XT Amplify program growth and recurring services. Product revenue grew 8% YoY to $145 million, while service revenue increased 10% YoY to $125 million.
- Non-GAAP gross margin was 42.1%, down 530bps QoQ due to lower product volumes and seasonal expenses. Non-GAAP EPS was $0.26 vs. $0.03 YoY.
- Tariffs on China-sourced components could impact 2025 non-GAAP EBITDA by $40M, with $5M in Q2 and $35M in H2. Mitigation efforts include nearshoring and dual sourcing.
- Secured new contracts with leading health systems in NJ, IL, and RI for XT Cabinets, anesthesia workstations, and specialty pharmacy services.

**【CFO Financial Commentary】**
- Q1 2025 non-GAAP EBITDA was $24 million, up 13% YoY but down 48% QoQ. Free cash flow was $10 million, with cash reserves at $387 million.
- Updated 2025 guidance: Total revenue $1.105B-$1.155B, non-GAAP EBITDA $100M-$145M (down from prior $110M-$160M range). Non-GAAP EPS $1.00-$1.65 (down from $1.20-$1.80).
- Tariff mitigation plans include accelerating component shipments from low-tariff regions and evaluating pricing strategies.

**【Q&A Key Takeaways】**
- **Tariff Impact Distribution**: Company absorbing full $40M EBITDA impact in 2025, no price increases passed to customers yet. 
- **Supply Chain Transition**: 3-year nearshore plan 1/3 complete. Semiconductors and metal frames are key China-sourced components.
- **Demand Environment**: Hospitals prioritizing pharmacy IT for outpatient expansion and specialty meds. Q1 bookings remain strong despite macro concerns.
- **Product Momentum**: XT Amplify rollout on track, IBX software release gaining traction with 6%+ hospital margins driving investments.


Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript

- **Revenue Recovery**: Q4 2024 revenue up 15% YoY to $307 million, with product revenue surging 37% YoY.
- **Profitability Breakthrough**: Q4 GAAP EPS of $0.34 marks return to GAAP profitability; Non-GAAP EBITDA up 17% YoY to $136 million.
- **Strategic Wins**: Secured multi-year contracts with NYC Health + Hospitals and a Fortune 25 insurer, expanding EnlivenHealth services.
- **2025 Growth Path**: Guided for $1.105-1.155 billion in 2025 revenue, with Non-GAAP EBITDA margin expansion of 100bps.
- **Robotics Momentum**: IVX Station robots now compatible with 60+ new drug vials, supporting 23% YoY growth in IVCS revenue.
- **ARR Acceleration**: Annual recurring revenue expected to grow to $610-630 million in 2025 (53% of total revenue), driven by specialty pharmacy and SaaS expansion.


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 total revenue of $307 million, up 15% YoY, driven by strong product revenue ($182 million, +37% YoY) and service revenue ($125 million, +11% YoY). 
- **Gross Margin Expansion**: Non-GAAP gross margin improved to 47.4% (vs. 44.5% Q3 2024), benefiting from higher product volumes and favorable mix.
- **Key Wins**: Secured multi-year contracts with NYC Health + Hospitals, North Carolina healthcare system, and a Fortune 25 health insurer for EnlivenHealth services.
- **2025 Outlook**: On track for consistent GAAP profitability, with Q1 2025 revenue guidance of $255-265 million and full-year total revenue of $1.105-1.155 billion.

**【CFO Financial Commentary】**
- **Profitability**: Q4 GAAP EPS of $0.34 (vs. -$0.32 Q4 2023), Non-GAAP EPS of $0.60 (vs. $0.33 Q4 2023). Full-year Non-GAAP EBITDA of $136 million exceeded revised guidance.
- **Cash Flow**: Q4 free cash flow of $43 million, ending 2024 with $369 million in cash. 2025 Non-GAAP EBITDA guidance of $140-155 million reflects 100bps margin expansion.
- **Bookings**: 2024 product bookings of $558 million (new metric), with 2025 guidance of $500-550 million. ARR expected to grow to $610-630 million (vs. $580 million 2024).

**【Q&A Highlights】**
- **Demand Trends**: Hospitals' improved financial health driving capital spending, with 2024 bookings up 79% YoY. XT Amplify adoption accelerating, with 60+ new NDCs enabled in IVX robots.
- **Gross Margin Leverage**: SaaS/Expert Services (14% YoY growth) and XTExtend (higher margins) driving margin expansion. 2025 gross margin expected to improve further.
- **Robotics Growth**: IVX Station installations expanding during IV fluid shortage, with 60+ new drug vial compatibilities added. Q4 2024 IVCS revenue up 23% YoY.
- **ARR Contribution**: SaaS/Expert Services now 53% of total revenue, with specialty pharmacy services growing double-digits. 2025 ARR expected to grow 5-7%.


Omnicell, Inc. (OMCL) Q4 2024 Earnings Call Transcript

Omnicell (OMCL)-30 Oct 24-2024 Q3 Earnings call transcript

Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript

Omnicell (OMCL)-2 May 24-2024 Q1 Earnings call transcript

Omnicell (OMCL)-8 Feb 24-2023 Q4 Earnings call transcript

Omnicell (OMCL)-2 Nov 23-2023 Q3 Earnings call transcript

- **Revenue Beat**: Q2 revenue $299M (+3% QoQ, -10% YoY), driven by 13% growth in advanced services. Full-year guidance raised to $1.16-1.2B.
- **Profit Growth**: Non-GAAP EPS $0.57 (vs. $0.39 prev. Q), with 2023 EPS now $1.75-2.00.
- **Customer Expansion**: 20-hospital inventory optimization deal, Florida health system adopting IV compounding, and 17% reduction in pharmacy call transfers for a northeast chain.
- **Challenges**: Labor shortages delaying projects, but 2023 bookings expected at lower end of $1B-1.1B range.
- **AI Focus**: Internal AI pilots underway, with potential for customer-facing solutions in 2024+.

**【CEO Summary Section】**
- **Q2 2023 Performance**: Total revenue of $299 million, exceeding guidance, driven by 13% growth in advanced services and strong cost management. Non-GAAP EPS of $0.57 beat expectations.
- **Customer Wins**: Expansion of inventory optimization services to 20 hospitals in the South; Florida health system adopting IV compounding and XT cabinets; Minnesota health system converting to Omnicell's XT fleet.
- **Market Trends**: Hospitals facing labor shortages and IT constraints delaying new tech adoption, but long-term demand for automation remains strong.
- **Leadership Updates**: New CFO Nchacha Etta and Board member Bobby Ghoshal join, emphasizing financial discipline and innovation.

**【CFO Financial Commentary】**
- **Q2 Financials**: GAAP net income $0.08, up from Q1 loss of $0.33. Non-GAAP EBITDA $47 million (+$20M vs. Q1), cash balance $399 million.
- **Guidance Adjustments**: Full-year revenue raised to $1.16-1.2B (prev. $1.1-1.15B), driven by higher service revenues. 2023 non-GAAP EPS now $1.75-2.00 (prev. $1.55-1.75).
- **Cost Management**: $50M annualized SG&A savings offset by inflation, with non-GAAP OpEx flat/down YoY.
- **Tax Impact**: 2023 blended tax rate ~11%, higher than prior estimate due to profit growth.

**【Q&A Highlights】**
- **Labor Constraints**: Hospitals delaying projects due to stretched IT and nursing staff, but Omnicell's advanced services help reduce labor needs.
- **Booking Trends**: Full-year bookings expected at lower end of $1B-1.1B range due to capital budget delays.
- **AI Strategy**: Internal AI pilots underway, with potential for customer-facing solutions in 2024+.
- **Product Upgrades**: XT cabinet upgrades >60% complete, with no immediate plans for new hardware cycle.
- **340B Impact**: CMS $9B rebate could accelerate spending on Omnicell solutions in Q4/2023-Q1/2024.

Omnicell (OMCL)-1 Aug 23-2023 Q2 Earnings call transcript

- **Revenue Resilience**: Q1 2023 revenue $291M exceeded guidance, driven by services (+12% YoY) and cost control. Non-GAAP EPS $0.39 beat expectations.
- **Cost Efficiency**: $50M annual savings from headcount reduction and office space rationalization offsetting 9% YoY revenue decline.
- **Strategic Growth**: EnlivenHealth 5-year retail agreement and specialty pharmacy wins highlight shift to recurring revenue models.
- **Operational Focus**: CIMM training center and ESG initiatives position Omnicell as healthcare automation leader.
- **Guidance Confidence**: Full year bookings and revenue reaffirmed, with 2H sequential growth expected from stable backlog.

**【CEO Summary Section】**
- **Market Challenges and Cost Management**: CEO Randall Lipps highlighted ongoing labor and capital budget constraints in healthcare. Omnicell reduced headcount by 9% and office space by 21%, targeting $50M annualized savings. 
- **Financial Performance**: Q1 2023 revenue $291M (down 9% YoY), non-GAAP EPS $0.39 (vs $0.83 YoY). Exceeded guidance due to revenue timing and cost control.
- **Customer Wins**: Secured new contracts with University of Iowa, Southern California health system, and Illinois health system for automation solutions.
- **Strategic Initiatives**: Launched Center for Innovation in Medication Management (CIMM) with Long Island University to train pharmacy students on Omnicell tech.
- **CFO Transition**: Incoming CFO search underway; current CFO Peter Kuipers to depart July 2023.

**【CCO (Scott Seidelmann) Update】**
- **Acquisition Integration**: ReCept (specialty pharmacy), FDS Amplicare (SaaS), and MarkeTouch Media now fully integrated into EnlivenHealth platform.
- **Services Growth**: Q1 services revenue $105M (+12% YoY). New wins include specialty pharmacy programs with Illinois and Texas health systems.
- **EnlivenHealth Expansion**: 5-year agreement with large retail chain to deploy digital engagement tools, targeting medication adherence.
- **CIMM Impact**: Training facility to enhance customer demos and implementation teams.

**【CFO Financial Commentary】**
- **Revenue**: Q1 product $181M (-10% YoY), services $105M (+12% YoY). Non-GAAP gross margin 44.8% (down 50bps vs prior qtr).
- **Cost Savings**: $14M nonrecurring Q1 charges ($8M asset impairments, $5M severance). Annualized savings from cost actions expected to offset inflation.
- **Cash Flow**: $340M cash balance. Free cash flow negative $1M due to timing, expected to improve.
- **Guidance**: Q2 2023 revenue $278-288M, non-GAAP EPS $0.25-0.35. Full year bookings, revenue, EBITDA, EPS reaffirmed.

**【Q&A Highlights】**
- **Product Demand**: XT upgrade cycle stable post-pandemic. Services growth driven by specialty pharmacy and CPDS wins.
- **Cost Management**: Flat to down OpEx YoY, with R&D investment. Flexible workforce used for implementations.
- **EnlivenHealth Momentum**: SaaS platform adoption accelerating in retail and hospital settings. 5-year retail agreement includes 100+ stores.
- **Macro Trends**: Slow improvement in hospital capital spending. Backlog visibility supports 2H growth.
- **Inflation**: Pricing offsets 50% of component cost increases. Semiconductor inventory sufficient for 2023.


Omnicell (OMCL)-2 May 23-2023 Q1 Earnings call transcript

- **Cost-Cutting Focus**: $50M annual savings from workforce reductions and real estate consolidation, offsetting macroeconomic challenges.
- **Advanced Services Growth**: 10% YoY revenue target for 2023, driven by Specialty Pharmacy and IV compounding wins.
- **Steady Product Demand**: XT upgrades and competitor conversions provide predictable revenue, despite cautious capital spending.
- **Financial Caution**: 2023 revenue guidance reflects lower bookings, but EBITDA margin expansion expected through cost actions and volume leverage.
- **Supply Chain Stability**: Semiconductors secured for 2023, mitigating supply chain risks.

**【CEO Summary Section】**
- CEO Randall Lipps emphasized a cautious approach to 2023, citing macroeconomic uncertainty and ongoing capital budget freezes among healthcare customers.
- Announced additional workforce reductions (totaling ~15% since November 2022) and real estate footprint reduction, targeting $50M annualized operating expense savings.
- Highlighted Advanced Services momentum, with over half of top 300 U.S. health systems now using Omnicell's services, including IV compounding and Specialty Pharmacy solutions.
- Noted stabilization in customer demand for connected devices, with a focus on ROI-driven investments.

**【CFO Financial Commentary】**
- 2022 GAAP revenue: $1.296B (14% YoY growth); Non-GAAP EPS: $3.00 (down 21% YoY due to lower operating leverage).
- Q4 2022 Non-GAAP EBITDA: $26M (vs. $61M in Q3 2022); Full year Non-GAAP EBITDA: $193M (15% margin).
- 2023 Guidance: 
  - Revenues: $1.15B-$1.19B (down 10%-15% YoY)
  - Advanced Services revenue: $200M-$210M (10% YoY growth)
  - Non-GAAP EPS: $1.55-$1.80
  - EBITDA: $120M-$135M (6-7% margin expansion)
- Expected 2023 savings: $50M from cost actions, offset by salary inflation and R&D investments.

**【Q&A Highlights】**
- **Advanced Services Growth**: Despite cautious 2023 guidance, management sees long-term potential, with Specialty Pharmacy and IV compounding services gaining traction.
- **Semiconductor Supply**: Secured $8M in Q4 2022 for 2023 needs, with pricing locked in; no immediate risk from geopolitical tensions.
- **Customer Capital Spend**: Health systems remain cautious on new device purchases, but upgrading aging infrastructure (e.g., XT replacements) provides steady demand.
- **Backlog Visibility**: Product backlog ($797M) includes long-term contracts, while Advanced Services backlog ($418M) reflects multiyear commitments.
- **CFO Transition**: Peter Kuipers will depart in July 2023 after 7 years, with a smooth transition planned.


Omnicell (OMCL)-28 Feb 23-2022 Q4 Earnings call transcript

Omnicell (OMCL)-2 Nov 22-2022 Q3 Earnings call transcript

Omnicell (OMCL)-7 Aug 22-2022 Q2 Earnings call transcript

Omnicell (OMCL)-1 May 22-2022 Q1 Earnings call transcript

Omnicell (OMCL)-15 Feb 22-2021 Q4 Earnings call transcript

Omnicell (OMCL)-2 Nov 21-2021 Q3 Earnings call transcript

Omnicell (OMCL)-31 Jul 21-2021 Q2 Earnings call transcript

Omnicell (OMCL)-1 May 21-2021 Q1 Earnings call transcript

Omnicell (OMCL)-2 Feb 21-2020 Q4 Earnings call transcript

- **Revenue Beat and Guidance**: Q3 revenue up 7% sequentially, with full-year bookings guidance reinstated. 2021 revenue expected to exceed long-term CAGR due to COVID timing dynamics.
- **Strategic Wins and Expansion**: 143 long-term sole source contracts signed, including first Central Pharmacy and international robotic dispensing deals. 340B acquisition adds $10 million Q4 revenue and high-growth tech-enabled services.
- **Operational Strength**: Non-GAAP EPS of $0.60 in Q3, 47.1% gross margin, and $27 million free cash flow. Capital structure strengthened with $575 million convertible notes issuance.
- **Future Growth Drivers**: Autonomous Pharmacy adoption accelerating, with Omnicell One and EnlivenHealth driving recurring revenue. International expansion and multi-product platform sales fueling double-digit growth.

**【CEO Summary Section】**
- **Revenue Recovery and Growth**: Q3 revenue of $214 million, up 7% sequentially, with bookings returning to pre-COVID levels. Reinstated full-year product bookings guidance of $865 million to $900 million, reflecting strong demand and delayed implementations.
- **Customer Wins and Strategy**: Added 2 new long-term sole source contracts (Lehigh Valley Health Network and Allegheny Health Network), bringing total to 143. Focus on Top 300 U.S. health systems, with over half now as customers. Autonomous Pharmacy strategy gaining traction, highlighted by wins in Central Pharmacy and international markets.
- **Tech-Enabled Services Expansion**: Launched Omnicell One (cloud-based optimization tool) and acquired 340B Link for $225 million, enhancing software-enabled services. EnlivenHealth partnerships with Walgreens and Walmart expand patient engagement capabilities.

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 non-GAAP EPS of $0.60, up $0.23 from Q2. Gross margin improved to 47.1% due to volume leverage. Free cash flow of $27 million driven by operating efficiency and inventory reductions.
- **Capital Structure**: Issued $575 million convertible notes, strengthening liquidity to $629 million. 2021 preliminary revenue guidance of $1.015 billion to $1.045 billion reflects timing of 2020 bookings and normalized demand.
- **Expense Management**: Full-year non-GAAP operating expenses guided to $310 million to $350 million, with modest increases in Q4 to support growth. Long-term targets include 10-12% organic revenue CAGR and 18% non-GAAP operating margin.

**【Q&A Highlights】**
- **340B Acquisition Impact**: Q4 contribution of $10 million in revenue and EPS accretion. Expected 20-25% growth in 2021, with cross-selling opportunities in existing customer base.
- **COVID-19 Impact**: Hospitals operating near 90% capacity, with elective surgeries resuming. No material delays in bookings despite recent case spikes.
- **International Growth**: Momentum in Middle East and Morocco, with multi-product platform deals driving higher-than-domestic growth rates.
- **Omnicell One Adoption**: Archbold Health and others set to go live, with recurring SaaS revenue model and multi-year contracts.


Omnicell (OMCL)-27 Oct 20-2020 Q3 Earnings call transcript

Omnicell (OMCL)-28 Jul 20-2020 Q2 Earnings call transcript

Omnicell (OMCL)-9 May 20-2020 Q1 Earnings call transcript

- **Record 2019 growth**: 14% revenue increase, $813M bookings, and 34% EPS rise highlight strong execution.
- **Autonomous pharmacy momentum**: 23% legacy system upgrades and multi-year deals drive long-term customer retention.
- **2020 outlook**: 9-13% revenue growth, targeting $1B+ and 18% operating margin by 2024.
- **IV compounding opportunity**: FDA restrictions accelerate adoption of Omnicell's semi-automated IV solutions.
- **Minimal COVID-19 risk**: No material impact expected from China operations.

**【CEO Opening Remarks】**
- **Record financial performance**: 2019 saw record product bookings ($813M, +14%), backlog ($588M, +23%), revenue ($897M, +14%), and non-GAAP EPS ($2.81, +34%).
- **Autonomous pharmacy vision**: Emphasized solving pharmacy challenges through automation, intelligence, and services. Highlighted new customer wins, including Fairview Health and a Pennsylvania/New Jersey health system, with multi-year sole-source agreements.
- **Market expansion**: Growing adoption of multi-product platforms, driving larger deal sizes and long-term customer relationships.

**【CFO Financial Review】**
- **Q4 2019 results**: Revenue $248M (+17% YoY), GAAP EPS $0.51 (+42%), non-GAAP EPS $0.77 (+10%). Full-year non-GAAP gross margin exceeded 50%, operating margin 14.8%.
- **2020 Guidance**: Product bookings $865-900M (+9% YoY midpoint), revenue $1.0-1.2B (+13%), non-GAAP EPS $2.96-3.16 (+9%).
- **Long-term framework**: 5-year CAGR targets of 10-12% for organic revenue, 18% non-GAAP operating margin by 2024.
- **COVID-19 impact**: Minimal expected operational or financial impact due to limited China exposure.

**【Q&A Highlights】**
- **Service offerings growth**: Professional services adoption growing, with 23% of legacy dispensing systems upgraded. Gross margin impact initially neutral, long-term expansion expected.
- **Hospital environment**: Consolidation driving strategic investments in automation. Omnicell's multi-product platform wins 70%+ of new deals.
- **IV compounding demand**: FDA 507B restrictions accelerating in-house IV compounding, benefiting Omnicell's IV workflow solutions.
- **Competitive positioning**: Unique platform combining automation, software, and services creates defensible market position.


Omnicell (OMCL)-6 Feb 20-2019 Q4 Earnings call transcript

- **Record Growth**: Q3 revenue $229M (+12% YoY), non-GAAP EPS $0.76 (+21% YoY), 17% operating margin.
- **Strategic Wins**: 10-year Mercy deal, Vizient expansion, Salem Health adoption, VA government wins.
- **Financial Strength**: Full year non-GAAP EPS guidance raised to $2.79-$2.84 (+35% YoY), $137M cash balance.
- **Autonomous Pharmacy Expansion**: Investing in automation, intelligence, and medication dispensing solutions.
- **Operational Efficiency**: DSO reduced to 82 days, free cash flow $42M in Q3.

**【CEO Summary Section】**
- **Record Financial Performance**: Q3 2019 revenue of $229 million (+12% YoY), non-GAAP EPS of $0.76 (+21% YoY), and 17% non-GAAP operating margin (up 180bps YoY).
- **Autonomous Pharmacy Vision**: Expanding into three key areas - automation, intelligence, and medication dispensing - to address industry challenges like prescription errors and opioid abuse.
- **Strategic Partnerships**: 
  - 10-year renewal with Mercy Health System for $100M+ in equipment and services.
  - 5-year expansion with Vizient for full product portfolio, including XR2 and IV workflow solutions.
  - Salem Health adoption of XT automated dispensing systems with EHR integration.
  - Government sector wins with VA Health Care Systems for XR2 and IV automation.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q3 product revenue up 12% YoY driven by XT Series implementations and population health solutions.
- **Profitability**: GAAP EPS of $0.46 (+36% YoY), non-GAAP EPS of $0.76 (+21% YoY). Full year 2019 non-GAAP EPS guidance raised to $2.79-$2.84 (+35% YoY).
- **Cash Flow**: Q3 free cash flow of $42M, cash balance of $137M, and net cash position of $57M.
- **Guidance**: Q4 2019 revenue $240-246M, full year 2019 revenue $889-895M (+13% YoY).
- **Margins**: Expecting 15%+ operating margin for full year, with investments in Autonomous Pharmacy solutions.

**【Q&A Highlights】**
- **Product Revenue Timing**: FX headwinds in UK and Middle East delayed Q3 shipments, but backlog remains strong.
- **Gross Margin Trends**: Product margins benefited from favorable mix, while service margins pressured by population health solutions and professional services investments.
- **Government Deal Flow**: Q3 is peak quarter for government business, with VA and NHS wins.
- **DSO Improvement**: Collections efforts reduced DSO to 82 days (down 11 days YoY).
- **SEC Inquiry**: Cooperating with SEC on July 2019 short-seller report, no material issues identified.


Omnicell (OMCL)-24 Oct 19-2019 Q3 Earnings call transcript

- **Revenue & Profit Growth**: Q2 2019 revenue $217 million (+15% YoY), Non-GAAP EPS $0.67 (+46% YoY), driven by XT Series and service expansion.
- **Backlog & Market Share**: Record backlog with 80% long-term deals; 1% U.S. hospital market share gains via new partnerships.
- **Financial Strength**: Net cash position achieved, $12 million free cash flow Q2, and narrowed 2019 Non-GAAP EPS guidance to $2.65-$2.82.
- **Strategic Momentum**: Autonomous Pharmacy vision advancing with automation, data analytics, and IV workflow solutions; competitive wins and renewals accelerate market penetration.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2019 revenue of $217 million, up 15% YoY, driven by XT Series implementations and service revenue growth.
- **Non-GAAP EPS**: $0.67, up 46% YoY, reflecting operational efficiency and scale.
- **Backlog**: Record-high product backlog, with 80% of deals anchored by long-term commitments.
- **Autonomous Pharmacy Vision**: Integration of automation, intelligence, and expert services; partnerships with Spartanburg, MUSC Health, St. Luke's, Northern Arizona, and Atrium (representing 1% U.S. hospital market share by bed count).

**【CFO Financial Commentary】**
- **GAAP Results**: Net income $420 million, GAAP EPS $0.37 (up 131% YoY).
- **Non-GAAP Guidance**: 2019 Non-GAAP EPS $2.65-$2.82 (midpoint +31% YoY).
- **Free Cash Flow**: $12 million Q2, with net cash position achieved for first time since 2016.
- **Debt Repayment**: $21 million Q2, reducing outstanding debt to $80 million.
- **Headcount**: 2,555 (up 131 YoY), focused on manufacturing, implementation, and service.

**【Q&A Highlights】**
- **Backlog Composition**: XT Series dominates short-term backlog; Performance Center, XR2, and services contribute to long-term deals.
- **DSO Trends**: 87 days Q2 (down 6 days QoQ), stable despite larger deal sizes.
- **Inventory Management**: Flat year-over-year at $104 million, optimized for growing demand.
- **Market Share**: Competitive wins (e.g., Northern Arizona) and renewals (Atrium) drive 1%-2% annual gains.
- **IV Workflow Strategy**: Robot-as-a-service model gains traction, offering efficiency over outsourcing or DIY.
- **Acquisition Strategy**: Open to tuck-in acquisitions enhancing platform value, with focus on accretive deals.

Omnicell (OMCL)-25 Jul 19-2019 Q2 Earnings call transcript

Omnicell (OMCL)-26 Apr 19-2019 Q1 Earnings call transcript

- **2018 Record Year**: $716M bookings (26% growth), $787M revenue (10% growth), $2.09 non-GAAP EPS (48% growth). 
- **Autonomous Pharmacy Momentum**: 90% of multi-million deals include multiple products; Texas Children’s Hospital and CDCR expanding platforms. 
- **2019 Guidance**: $745M-$780M bookings, $880M-$900M revenue, $2.40-$2.60 non-GAAP EPS. 
- **Key Trends**: XT Series upgrades driving growth, 49.3% non-GAAP gross margin, $478M total backlog. 
- **Strategic Focus**: Autonomous Pharmacy expansion, limited M&A, international market penetration.

**【CEO Summary Section】**
- **Record 2018 Performance**: Achieved $716M in bookings (26% YoY), $787M revenue (10% YoY), and $2.09 non-GAAP EPS (48% YoY growth). 
- **New Product Momentum**: Launched XR2 Central Pharmacy Robot and IVX Workflow, driving multi-product platform sales. 
- **Autonomous Pharmacy Vision**: Focused on automating medication workflows through cloud-based intelligence, with examples like Texas Children’s Hospital and California Department of Corrections expanding Omnicell platforms. 
- **Market Leadership**: XT Series automated dispensing cabinets awarded 'Best in Class' for 13th consecutive year.

**【CFO Financial Commentary】**
- **Q4 2018 Results**: $212M GAAP revenue (8% YoY), $0.36 GAAP EPS, $0.70 non-GAAP EPS (27% YoY). Full year non-GAAP EPS of $2.09 (48% YoY). 
- **Gross Margin Expansion**: Non-GAAP gross margin 49.3% (up 200bps YoY). 
- **2019 Guidance**: 
  - Product bookings: $745M-$780M (7% organic growth). 
  - Total revenue: $880M-$900M (13% YoY). 
  - Non-GAAP EPS: $2.40-$2.60 (20% YoY). 
  - Q1 2019 revenue: $196M-$202M. 
- **Long-Term Backlog**: $478M total backlog (39% YoY), with $103M classified as multi-year agreements.

**【Q&A Highlights】**
- **XT Upgrade Cycle**: Expecting continued strong growth, with 90% of multi-million dollar deals involving multiple products. 
- **M&A Strategy**: Focused on organic growth of Autonomous Pharmacy platform, with limited large-scale acquisitions. 
- **Patient Engagement**: Early-stage payer contracts showing promise, with potential to expand into provider networks. 
- **International Growth**: Targeting UK, Middle East, Australia, Germany, and France for automation adoption. 
- **Segment Performance**: Automation & Analytics segment grew 12% YoY, while Medication Adherence segment faces timing challenges but benefits from integrated sales strategy.

Actual											0.66	0.37	0.6	0.91	0.83	0.97	1.08	0.92	0.83	0.84	1	0.33	0.39	0.57	0.62	0.33	0.03	0.51	0.56	0.6	0.26	0.45	0.51	0.4	0.55	0.94
Forecast											0.5117	0.2288	0.4871	0.8114	0.6567	0.8267	0.9125	0.923	0.685	0.85	0.9544	0.0822	0.0676	0.2822	0.4657	0.1539	-0.0932	0.1443	0.4192	0.5835	0.2046	0.27	0.3625	0.4963	0.3313	0.4675
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+28.98%	+61.71%	+23.18%	+12.15%	+26.39%	+17.33%	+18.36%	-0.33%	+21.17%	-1.18%	+4.78%	+301.46%	+476.92%	+101.98%	+33.13%	+114.42%	+132.19%	+253.43%	+33.59%	+2.83%	+27.08%	+66.67%	+40.69%	-19.40%	+66.01%	+101.07%

OMCL

OMCL

Omnicell (OMCL) Earnings

OMCL Q2 2026 Earnings

EPS

Revenue

Earnings Call

You can ask Aime

OMCL

Omnicell (OMCL) Earnings

OMCL Q2 2026 Earnings

EPS

Revenue

Earnings Call

OMCL Earnings Call Summary for Q2/20268:30 AM on Jul 30, 2026

OMCL Earnings Call Summary for Q1/20268:30 AM on Apr 28, 2026

OMCL Earnings Call Summary for Q4/20258:30 AM on Feb 5, 2026

OMCL Earnings Call Summary for Q3/20258:30 AM on Oct 30, 2025

OMCL Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

You can ask Aime